Correction

Resolutions from the Annual General Meeting of Novo Nordisk A/S

Correction due to missing pdf-file. 

Bagsværd, Denmark, 25 March 2021 - Today, Novo Nordisk A/S held its Annual General Meeting.

At the Annual General Meeting, Helge Lund, chair of the of Board of Directors stated: “In 2020, Novo Nordisk showed agility and resilience in very challenging times, and the COVID-19 pandemic has underscored the importance of continued innovation and relevance of businesses in times of crisis. We have delivered on our financial guidance and invested significantly in commercial launches and research and development. All in all, we are very satisfied with the progress made on our strategic aspirations, which has resulted in an attractive capital allocation to shareholders.” He continued: “Despite the pandemic and turbulent business environment, Novo Nordisk made important steps towards delivering on our purpose of driving change to defeat diabetes and other serious chronic diseases”.

Resolutions adopted at the Annual General Meeting

Financial year 2020 and board remuneration

• Approval of the Company’s statutory Annual Report 2020 and distribution of profits according to the statutory Annual Report 2020.
• The final dividend for 2020 of DKK 5.85 for each Novo Nordisk A or B share of DKK 0.20. The total dividend for 2020 of DKK 9.10 includes both the interim dividend of DKK 3.25 for each Novo Nordisk A and B share of DKK 0.20 which was paid in August 2020 and the final dividend of DKK 5.85 for each Novo Nordisk A and B share of DKK 0.20 to be paid in March 2021.
• The Remuneration Report 2020 was approved (advisory vote).
• The actual remuneration of the Board of Directors for 2020 and the remuneration level for 2021 were approved.

Elections

• Re-election of Helge Lund as chair of the Board of Directors.
• Re-election of Jeppe Christiansen as vice chair of the Board of Directors.
• Re-election of Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Kasim Kutay and Martin Mackay as members of the Board of Directors.
• Election of Henrik Poulsen as new member of the Board of Directors.
• Appointment of Deloitte Statsautoriseret Revisionspartnerselskab as the Company’s auditor.

Shares and capital

• Reduction of the Company’s B share capital by cancellation of part of the Company’s own holding of B shares. The Company’s B share capital is reduced by DKK 8,000,000 from DKK 362,512,800 to DKK 354,512,800. The Company’s A share capital of DKK 107,487,200 remains unchanged, whereby the Company’s share capital will amount to DKK 462,000,000.
• Authorisation to the Board of Directors until the Annual General Meeting 2022 to allow the Company to repurchase own shares of up to 10% of the share capital subject to a holding limit of 10% of the share capital.
• Cancellation of Article 5.3 of the company’s Articles of Association.
• Extension of the authorisation to the Board of Directors to increase the Company's share capital for a period of one year until 25 March 2023 up to nominally DKK 46,200,000.    

Other